Daebong LS is showing strong performance. The news that the company has succeeded in developing and commercializing an all-in-one adhesive hydrogel for localized wound care appears to be influencing its stock price. This achievement represents a significant advancement in the field of wound treatment, drawing attention as a new technology that protects the skin from micro-wounds and strengthens the skin barrier.
As of 9:41 AM on the 28th, Daebong LS is trading at 15,050 KRW, up 25.0% from the previous day.
Daebong LS explained that most human organs are covered with mucous membranes, which are difficult to adhere to and suture, easily causing bleeding. Therefore, there is a need for bio-tissue bonding material technology with strong adhesion and biocompatibility to overcome this challenge. Bio-tissue adhesives are medical devices used in various clinical fields such as wound suturing and hemostasis of internal and external human tissues. With the global aging population, the related market is rapidly growing due to advantages such as ease of procedure, time efficiency, and aesthetics.
Using the world’s first new concept skin adhesion technology developed by Daebong LS, it is possible to achieve not only wound suturing but also additional effects such as blocking harmful substances and moisturizing. While existing products lose adhesion in the presence of moisture, this product is moisture-friendly and achieves rapid wound closure, providing an immediate effect.
According to Daebong LS Research Institute, the hydrogel penetrates micro-scratches on the skin, attracting moisture within the skin to increase cohesion and significantly improve skin adhesion. It demonstrated excellent efficacy in restoring damaged skin barriers, moisturizing, and improving keratin. Since it performs best at a skin pH between 5.5 and 5.8, hydrogels developed using this technology can be applied to treat wounds of various sizes and depths.
The research results were published in the ‘Chemical Engineering Journal’ (IF: 16.7), a prestigious academic journal ranked within the top 3% in the chemical engineering field according to JCR. This presents new possibilities in the field of wound treatment. Additionally, Daebong LS has filed two patents for skin tissue bonding compositions and their manufacturing methods for wound healing and regeneration, as well as topical skin compositions.
According to Daebong LS Research Institute, “Currently, more than ten domestic derma-specialized companies are developing innovative derma products using this material.” They added, “Meanwhile, this technology has gained recognition through international papers and has attracted significant interest from ‘Flen Health,’ a Luxembourg-based company leading the skin wound treatment field in Europe. We expect concrete export results, including signing an NDA.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
